Pharvaris
Christa Milley is currently the Vice President of Business Development at Pharvaris, a position held since October 2024. Prior to this, Christa served as the Executive Director of Business Development at Omega Therapeutics from April 2021 to October 2024, where significant contributions were made in building the business development function as the company transitioned from a preclinical startup to a public entity. Christa's experience includes serving as the Director of Global Transactions at Sanofi Genzyme, leading cross-functional transactions across specialty care divisions, and as the Director of Business Development at Solid Biosciences, where the business development function was developed from the ground up. Earlier roles at Solid Biosciences included Associate Director and Senior Manager of Business Development. Christa's career began at Morningside, where roles included Paralegal, Analyst, and Project Leader, focusing on investment documents and legal groundwork. Academic credentials include an MBA from the MIT Sloan School of Management and a Bachelor’s degree from Boston University.
This person is not in any teams
This person is not in any offices
Pharvaris
2 followers
Pharvaris is a preclinical stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (HAE) and other B2 receptor-mediated indications. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.